# A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

> **NCT00124111** · PHASE2 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pegfilgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** methotrexate
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT00124111
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124111, "A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00124111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*